| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -1.7 | -2.1 |
| EPS (diluted, $ a share) | $-0.14 | $-0.19 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, BCLI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Brainstorm Cell Therapeutics Inc.: key numbers
- Share price
- $0.9000Close, Nov 16
- Market cap
- $9.93M
- Shares outstanding
- 11.03MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Brainstorm Cell Therapeutics Inc.
All →Brainstorm Cell Therapeutics Financial Results
BrainStorm Cell Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update on its Phase 3b ENDURANCE study of NurOwn in ALS. The company highlighted the appointment of former FDA official Professor Peter J. Pitts as Executive Chairman to lead regulatory and capital-markets initiatives. Net loss for the quarter was $2.1 million, or $0.03 per share, as the company prepares for the initiation of its next clinical trial phase.
- Term
- Q3 2026
“ALS remains a devastating disease with a critical unmet medical need, and patients urgently need new therapeutic options. We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn® in ALS, supported by an FDA-agreed protocol under a Special Protocol Assessment.”
Chaim Lebovits, President and Chief Executive Officer